<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" nameag="viewport"/>
<title>Primary Headache (Part 1)</title>
<script src="https://cdn.tailwindcss.com"></script>
<script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
<script src="https://cdn.jsdelivr.net/npm/canvas-confetti@1.6.0/dist/confetti.browser.min.js"></script>
<style>
        /* Custom styles for enhanced aesthetics and responsiveness */
        .option-btn {
            transition: all 0.3s ease;
            box-shadow: 0 2px 4px rgba(0, 0, 0, 0.1);
        }
        .option-btn:hover, .option-btn:active {
            transform: scale(1.02);
            box-shadow: 0 4px 8px rgba(0, 0, 0, 0.2);
        }
        .option-btn.selected {
            background-color: #3b82f6;
            color: white;
        }
        .marked {
            background-color: #fef08a;
        }
        .progress-bar {
            transition: width 0.5s ease-in-out;
            background: linear-gradient(to right, #3b82f6, #22c55e);
            box-shadow: 0 2px 4px rgba(0, 0, 0, 0.2);
            animation: pulse 2s infinite;
        }
        @keyframes pulse {
            0% { opacity: 1; }
            50% { opacity: 0.8; }
            100% { opacity: 1; }
        }
        .question-nav-btn, .result-nav-btn-grid {
            width: 40px;
            height: 40px;
            display: flex;
            align-items: center;
            justify-content: center;
            border-radius: 8px;
            font-size: 16px;
            touch-action: manipulation;
            transition: all 0.2s ease;
        }
        .question-nav-btn:hover, .question-nav-btn:active, .result-nav-btn-grid:hover, .result-nav-btn-grid:active {
            transform: scale(1.05);
        }
        .answered {
            background-color: #22c55e;
            color: white;
        }
        .unanswered {
            background-color: #e5e7eb;
        }
        .marked-nav {
            border: 2px solid #fef08a;
        }
        .video-container, .audio-container {
            display: none;
            position: relative;
        }
        .video-container.active, .audio-container.active {
            display: block;
            animation: fadeIn 0.5s ease-in;
        }
        @keyframes fadeIn {
            from { opacity: 0; }
            to { opacity: 1; }
        }
        .section-transition {
            transition: opacity 0.3s ease;
        }
        .section-transition.hidden {
            opacity: 0;
            pointer-events: none;
        }
        .result-nav {
            display: flex;
            justify-content: space-between;
            align-items: center;
            margin-top: 1rem;
        }
        .result-nav-btn {
            background-color: #4b5563;
            color: white;
            padding: 0.5rem 1rem;
            border-radius: 8px;
            transition: all 0.2s ease;
        }
        .result-nav-btn:hover, .result-nav-btn:active {
            background-color: #374151;
            transform: scale(1.05);
        }
        .result-nav-btn:disabled {
            background-color: #d1d5db;
            cursor: not-allowed;
        }
        .error-message {
            color: #dc2626;
            font-weight: bold;
            margin-top: 1rem;
        }
        /* Mobile-specific adjustments */
        @media (max-width: 640px) {
            .question-nav-btn, .result-nav-btn-grid {
                width: 38px;
                height: 38px;
                font-size: 14px;
            }
            .nav-panel, .results-nav-panel {
                width: 100%;
                max-width: 100%;
                overscroll-behavior: contain;
            }
            .option-btn {
                padding: 12px;
                font-size: 14px;
            }
            .header-text {
                font-size: 1.5rem;
            }
            .subheader-text {
                font-size: 0.875rem;
            }
            .button-group, .result-nav {
                flex-direction: column;
                gap: 0.5rem;
            }
            .result-nav-btn {
                width: 100%;
                text-align: center;
            }
        }
        /* Dark mode styles */
        .dark .bg-gray-100 {
            background-color: #1f2937;
        }
        .dark .bg-white {
            background-color: #374151;
        }
        .dark .text-gray-700 {
            color: #d1d5db;
        }
        .dark .text-gray-800 {
            color: #e5e7eb;
        }
        .dark .bg-gray-200 {
            background-color: #4b5563;
        }
        .dark .border {
            border-color: #4b5563;
        }
        .dark .bg-blue-500 {
            background-color: #2563eb;
        }
        .dark .hover\:bg-blue-600:hover {
            background-color: #1d4ed8;
        }
        .dark .bg-yellow-300 {
            background-color: #b45309;
            color: white;
        }
        .dark .hover\:bg-yellow-400:hover {
            background-color: #92400e;
        }
        .dark .bg-green-500 {
            background-color: #15803d;
        }
        .dark .hover\:bg-green-600:hover {
            background-color: #166534;
        }
        .dark .bg-gray-500 {
            background-color: #4b5563;
        }
        .dark .hover\:bg-gray-600:hover {
            background-color: #374151;
        }
        .dark .result-nav-btn, .dark .result-nav-btn-grid {
            background-color: #2563eb;
        }
        .dark .result-nav-btn:hover, .dark .result-nav-btn:active, .dark .result-nav-btn-grid:hover, .dark .result-nav-btn-grid:active {
            background-color: #1d4ed8;
        }
        .dark .result-nav-btn:disabled, .dark .result-nav-btn-grid:disabled {
            background-color: #4b5563;
        }
        .video-placeholder {
            width: 400px;
            height: 300px;
            background-color: #f0f0f0;
            display: flex;
            align-items: center;
            justify-content: center;
            cursor: pointer;
            margin-top: 10px;
            border-radius: 8px;
            border: 1px solid #ccc;
        }
        .play-icon {
            font-size: 40px;
            color: #007bff;
        }
        .video-loading {
            position: absolute;
            top: 50%;
            left: 50%;
            transform: translate(-50%, -50%);
            border: 4px solid #f3f3f3;
            border-top: 4px solid #3b82f6;
            border-radius: 50%;
            width: 40px;
            height: 40px;
            animation: spin 1s linear infinite;
        }
        @keyframes spin {
            0% { transform: translate(-50%, -50%) rotate(0deg); }
            100% { transform: translate(-50%, -50%) rotate(360deg); }
        }
    </style>

<script>
    // --- GEMINI AUTO-CAPTURE LISTENER ---
    // This function runs immediately after the quiz determines an answer is INCORRECT.
    function captureMistake(questionIndex, questionsData) {
        try {
            const item = questionsData[questionIndex];
            // Use the question text as a unique, stable identifier
            const uniqueId = 'srs_quiz_' + btoa(item.text.substring(0, 50)).replace(/=/g, ''); 

            // 1. Clean and simplify the explanation for storage
            let explanationText = item.explanation || item.correct_answer || "No explanation provided.";
            
            // Strip complex HTML (images, lists) and boilerplate text
            explanationText = explanationText.replace(/<img[^>]*>/g, "[IMAGE]").trim(); // Replace images with placeholder
            explanationText = explanationText.replace(/<p><strong>Ans\. [A-Z]\).*/i, "").trim(); // Remove the repeated Answer line
            explanationText = explanationText.replace(/<p><strong>Educational Objective:<\/strong>.*?<\/p>/gs, "").trim(); // Remove EO block
            explanationText = explanationText.replace(/@dams_new_robot/g, "");
            explanationText = explanationText.replace(/<\/?[^>]+(>|$)/g, " ").trim(); // Final strip of remaining tags

            // 2. Prepare card data
            const cardData = {
                text: item.text,
                answer: item.correct_answer,
                explanation: explanationText.substring(0, 500), // Keep explanations short
                nextReview: 0, // Due immediately
                reviews: 0,
                source: document.title.split('-')[0].trim() || 'Quiz'
            };

            // 3. Save to Local Storage (SRS Bank)
            localStorage.setItem(uniqueId, JSON.stringify(cardData));
            
            console.log(`ðŸ§  Captured Mistake #${questionIndex + 1} from ${document.title}`);

        } catch (e) {
            console.error("SRS Capture Failed:", e);
        }
    }
    // --- END GEMINI AUTO-CAPTURE LISTENER ---
</script>

</head>
<body class="bg-gray-100 font-sans transition-colors duration-300 min-h-screen overflow-y-auto">
<!-- Header Section -->
<header class="bg-blue-600 text-white p-4 shadow-lg">
<div class="container mx-auto">
<h1 class="text-2xl md:text-3xl font-bold header-text">Primary Headache (Part 1)</h1>
<p class="mt-2 text-sm md:text-base subheader-text">
                28 Questions | 28 Total Marks | 38 min Duration | ~81.43 sec/question
            </p>
<button class="mt-2 bg-gray-200 text-gray-800 px-3 py-1 rounded-lg hover:bg-gray-300 transition dark:bg-gray-600 dark:text-white" id="theme-toggle">
                Toggle Dark Mode
            </button>
</div>
</header>
<!-- Instructions Section -->
<section class="container mx-auto p-4 md:p-6 section-transition" id="instructions">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<h2 class="text-xl font-semibold mb-4">Instructions</h2>
<ul class="list-disc list-inside space-y-2 text-gray-700">
<li>This test contains 28 multiple choice questions.</li>
<li>Each question has only one correct answer.</li>
<li>You will have 38 minutes to complete the test.</li>
<li>Click or tap on an option to select your answer.</li>
<li>Use the "Mark for Review" button to revisit questions.</li>
<li>Navigate using Previous/Next buttons or the Questions Navigation panel.</li>
<li>Click "Submit" to finish and view results.</li>
<li>The test will auto-submit when time runs out.</li>
</ul>
<div class="mt-6 flex space-x-4 button-group md:flex-row flex-col">
<button class="bg-blue-500 text-white px-6 py-2 rounded-lg hover:bg-blue-600 transition" id="start-test">Start Test</button>


</div>
<div class="error-message hidden" id="error-message"></div>
</div>
</section>
<!-- Quiz Section -->
<section class="container mx-auto p-4 md:p-6 hidden section-transition" id="quiz">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<!-- Progress Bar -->
<div class="w-full bg-gray-200 rounded-full h-3 mb-4">
<div class="progress-bar h-3 rounded-full" id="progress-bar" style="width: 0%"></div>
</div>
<!-- Question Header -->
<div class="flex flex-col md:flex-row justify-between items-center mb-4">
<h2 class="text-lg font-semibold" id="question-number">Question <span>1</span> of 28</h2>
<p class="text-lg font-semibold mt-2 md:mt-0" id="timer">Time Remaining: <span>00:00</span></p>
</div>
<!-- Question Content -->
<div class="mb-6" id="question-content">
<p class="text-gray-800 mb-4" id="question-text"></p>
<div class="flex flex-wrap gap-4 mb-4" id="question-images"></div>
<div class="space-y-3" id="options"></div>
</div>
<!-- Navigation Buttons -->
<div class="flex flex-col md:flex-row justify-between items-center gap-2 md:gap-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition w-full md:w-auto" disabled="" id="previous-btn">Previous</button>
<button class="bg-yellow-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-yellow-400 transition w-full md:w-auto" id="mark-review">Mark for Review</button>
<button class="bg-blue-500 text-white px-4 py-2 rounded-lg hover:bg-blue-600 transition w-full md:w-auto" id="next-btn">Next</button>
<button class="bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full md:w-auto" id="nav-toggle">Questions Navigation</button>
<button class="bg-green-500 text-white px-4 py-2 rounded-lg hover:bg-blue-600 transition w-full md:w-auto" id="submit-test">Submit Test</button>
</div>
</div>
</section>
<!-- Results Section -->
<section class="container mx-auto p-4 md:p-6 hidden section-transition" id="results">
<div class="bg-white rounded-lg shadow-md p-5 md:p-8 md:p-5 md:p-8 min-h-screen md:min-h-0 md:rounded-lg md:shadow-md rounded-none shadow-none flex flex-col justify-between">
<h2 class="text-2xl font-semibold mb-4">Primary Headache (Part 1) - Results</h2>
<div class="grid grid-cols-1 md:grid-cols-2 gap-4 mb-6">
<p><strong>Correct:</strong> <span id="correct-count">0</span></p>
<p><strong>Wrong:</strong> <span id="wrong-count">0</span></p>
<p><strong>Unanswered:</strong> <span id="unanswered-count">0</span></p>
<p><strong>Marked for Review:</strong> <span id="marked-count">0</span></p>
</div>
<h3 class="text-lg font-semibold mb-4" id="result-question-number">Question <span>1</span> of 28</h3>
<div class="space-y-6" id="results-content"></div>
<div class="result-nav">
<button aria-label="Previous question result" class="result-nav-btn" disabled="" id="prev-result">Previous</button>
<button aria-label="Toggle results navigation panel" class="result-nav-btn" id="results-nav-toggle">Results Navigation</button>
<button aria-label="Next question result" class="result-nav-btn" id="next-result">Next</button>
</div>
<div class="mt-6 flex space-x-4 button-group md:flex-row flex-col">
<button class="bg-blue-500 text-white px-6 py-2 rounded-lg hover:bg-blue-600 transition" id="take-again">Take Again</button>
<button class="bg-gray-500 text-white px-6 py-2 rounded-lg hover:bg-gray-600 transition" id="review-test">Review Test</button>
</div>
</div>
</section>
<!-- Exit Confirmation Modal -->
<div class="fixed inset-0 bg-black bg-opacity-50 flex items-center justify-center hidden" id="exit-modal">
<div class="bg-white rounded-lg p-6 max-w-sm w-full">
<h2 class="text-xl font-semibold mb-4">Leave Test?</h2>
<p class="text-gray-700 mb-4">Your progress will be lost if you leave this page. Are you sure you want to exit?</p>
<div class="flex justify-end space-x-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition" id="continue-test">No, Continue</button>
<button class="bg-red-500 text-white px-4 py-2 rounded-lg hover:bg-red-600 transition" id="exit-test">Yes, Exit</button>
</div>
</div>
</div>
<!-- Submit Confirmation Modal -->
<div class="fixed inset-0 bg-black bg-opacity-50 flex items-center justify-center hidden" id="submit-modal">
<div class="bg-white rounded-lg p-6 max-w-sm w-full">
<h2 class="text-xl font-semibold mb-4">Confirm Submission</h2>
<p class="text-gray-700 mb-2">You have attempted <span id="attempted-count">0</span> of 28 questions.</p>
<p class="text-gray-700 mb-4"><span id="unattempted-count">0</span> questions are unattempted.</p>
<div class="flex justify-end space-x-4">
<button class="bg-gray-300 text-gray-700 px-4 py-2 rounded-lg hover:bg-gray-400 transition" id="cancel-submit">Cancel</button>
<button class="bg-green-500 text-white px-4 py-2 rounded-lg hover:bg-green-600 transition" id="confirm-submit">Submit Test</button>
</div>
</div>
</div>
<!-- Quiz Navigation Panel -->
<div class="fixed inset-y-0 right-0 nav-panel bg-white shadow-lg p-4 hidden overflow-y-auto" id="nav-panel">
<h2 class="text-lg font-semibold mb-4">Questions Navigation</h2>
<div class="mb-4">
<select class="w-full p-2 border rounded-lg text-gray-700" id="nav-filter">
<option value="all">All Questions</option>
<option value="answered">Answered</option>
<option value="unanswered">Unanswered</option>
<option value="marked">Marked for Review</option>
</select>
</div>
<div class="grid grid-cols-5 gap-2 md:gap-3" id="nav-grid"></div>
<button class="mt-4 bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full" id="close-nav">Close</button>
</div>
<!-- Results Navigation Panel -->
<div class="fixed inset-y-0 right-0 results-nav-panel bg-white shadow-lg p-4 hidden overflow-y-auto" id="results-nav-panel">
<h2 class="text-lg font-semibold mb-4">Results Navigation</h2>
<div class="mb-4">
<select class="w-full p-2 border rounded-lg text-gray-700" id="results-nav-filter">
<option value="all">All Questions</option>
<option value="answered">Answered</option>
<option value="unanswered">Unanswered</option>
<option value="marked">Marked for Review</option>
</select>
</div>
<div class="grid grid-cols-5 gap-2 md:gap-3" id="results-nav-grid"></div>
<button class="mt-4 bg-gray-500 text-white px-4 py-2 rounded-lg hover:bg-gray-600 transition w-full" id="close-results-nav">Close</button>
</div>
<!-- JavaScript Logic -->
<script>
        // Enable debug mode for detailed logging
        const DEBUG_MODE = true;

        // Log debug messages
        function debugLog(message) {
            if (DEBUG_MODE) {
                console.log(`[DEBUG] ${message}`);
            }
        }

        // Initialize questions with error handling
        let questions = [];
        let currentResultQuestion = 0; // State for current question in results
        try {
            debugLog("Attempting to parse questions_json");
            questions = [{"text": "Which of the following mutations is known to be present in most of the patients with familial hemiplegic migraine?", "options": [{"label": "A", "text": "The Cav2.1 (P/Q)â€“type voltage-gated calcium channel CACNA1A gene", "correct": true}, {"label": "B", "text": "The Na+-K+ATPase ATP1A2 gene designated FHM 2", "correct": false}, {"label": "C", "text": "The neuronal voltage-gated sodium channel SCN1A", "correct": false}, {"label": "D", "text": "The Na+-K+ATPase ATP1A2 gene designated FHM 3", "correct": false}], "correct_answer": "A. The Cav2.1 (P/Q)â€“type voltage-gated calcium channel CACNA1A gene", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>The Cav2.1 (P/Q)â€“type voltage-gated calcium channel CACNA1A gene Migraine genes identified by studying families with familial hemiplegic migraine (FHM) reveal the involvement of ion channels , suggesting that alterations in membrane excitability can predispose to migraine.</p>\n<p><strong>Highyeild:</strong></p><p>Familial hemiplegic migraine (FHM) Involved channel Gene FHM1 Most common 50%cases Cav 2.1 (P/Q)â€“type voltage-gated calcium channel CACNA1A gene FHM2 20%cases Na+-K+ATPase ATP1A2 gene FHM3 Neuronal voltage-gated sodium channel SCN1A gene</p>\n<p><strong>Random:</strong></p><p>Explanation For Incorrect Options:- Option: B &C. FHM1 is more common than FHM2,3. Option: D. the Na+K+ATPase-ATP1A2 gene causes FHM2 not FHM3.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Environmental and sensory stimuli in migraineurs can act as what factor for headache?", "options": [{"label": "A", "text": "Amplifying factor only", "correct": false}, {"label": "B", "text": "Initiating factor only", "correct": false}, {"label": "C", "text": "Amplifying or initiating factor", "correct": true}, {"label": "D", "text": "Resolving factor", "correct": false}], "correct_answer": "C. Amplifying or initiating factor", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Amplifying or initiating factor Environmental and sensory stimuli in migraineurs can act as both initiating factors and amplifying factors for headaches.</p>\n<p><strong>Highyeild:</strong></p><p>Migraineurs Sensitive to environmental and sensory stimuli Migraine-prone patients do not habituate easily to sensory stimuli. This sensitivity is amplified in women during the menstrual cycle. Headache can be initiated or amplified by various triggers Glare Bright lights Sounds Hunger let-down from stress Physical exertion Stormy weather Barometric pressure changes Hormonal fluctuations during menses L ack of or excess sleep alcohol nitrates. Knowledge of a patientâ€™s susceptibility to specific triggers can be useful in management strategies involving lifestyle adjustments , although it is becoming recognized that some apparent triggers may in fact be part of the initial phase of the attack ; i.e., the premonitory phase or prodrome.</p>\n<p><strong>Random:</strong></p><p>Explanation For All Options:- Option: A , B. Option C is better. Option: D. Amplifies NOT Resolves.</p>\n<p><strong>Extraedge:</strong></p><p>Pathophysiology of Migraine :</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following is the most common headache-related, and indeed neurologic, cause of disability in the world?", "options": [{"label": "A", "text": "Tension-type headache", "correct": false}, {"label": "B", "text": "Migraine", "correct": true}, {"label": "C", "text": "Stroke", "correct": false}, {"label": "D", "text": "Cluster headache", "correct": false}], "correct_answer": "B. Migraine", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Migraine Migraine, the second most common cause of headache , and the most common headache-related , and indeed neurologic , cause of disability in the world, afflicts ~15 percent of women and 6 percent of men over a 1-year period.</p>\n<p><strong>Random:</strong></p><p>Explanation For Incorrect Options:- Option: A.Tension-type headache - is reported to be the most common primary headache syndrome. Option: C. Stroke - is the second leading cause of death worldwide. Option: D. Cluster headache - is a relatively rare form of primary headache , although Nonetheless a common condition, with a population frequency of ~0.1 percent.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "The most frequent symptom of migraine is?", "options": [{"label": "A", "text": "Photophobia", "correct": false}, {"label": "B", "text": "Visual disturbance", "correct": false}, {"label": "C", "text": "Nausea", "correct": true}, {"label": "D", "text": "Photopsia", "correct": false}], "correct_answer": "C. Nausea", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Nausea Most frequent symptom of Migraine is nausea with 87 percent frequency.</p>\n<p><strong>Highyeild:</strong></p><p>SYMPTOM PATIENTS AFFECTED, % Nausea 87 Photophobia 82 Lightheadedness 72 Scalp tenderness 65 Vomiting 56 Visual disturbances 36 Paresthesias 33 Vertigo 33 Photopsia 26 Alteration of consciousness 18 Diarrhea 16 Fortification spectra 10 Syncope 10 Seizure 4 Confusional state 4</p>\n<p><strong>Random:</strong></p><p>Explanation For Incorrect Options:- Option: A. Photophobia- 82 percent. Option: B. Visual disturbance- 36 percent . Option: D. Photopsia- 26 percent .</p>\n<p><strong>Extraedge:</strong></p><p>Strongest predictor of migraine diagnosis PIN the diagnosis P -Photophobia I -Impairment/disability N -Nausea Any 2 + â†’ 93% PPV 3/3 + â†’ 98% PPV</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 25-year-old patient presented with a complaint of severe unilateral headache associated with nausea and weakness of the right half of the body. He has a family history of the same. Further investigations and detailed examination revealed the patient to be suffering from Familial hemiplegic migraine. According to the International headache society 2018 Familial hemiplegic migraine is classified under which of the following ?", "options": [{"label": "A", "text": "Migraine without aura", "correct": false}, {"label": "B", "text": "Migraine with aura", "correct": true}, {"label": "C", "text": "Probable migraine", "correct": false}, {"label": "D", "text": "Chronic migraine", "correct": false}], "correct_answer": "B. Migraine with aura", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Migraine with aura Familial hemiplegic migraine is under Hemiplegic migraine which is under Migraine with aura.</p>\n<p><strong>Highyeild:</strong></p><p>Migraine Migraine without aura Migraine with aura Migraine with typical aura Typical aura with headache Typical aura without headache Migraine with brainstem aura Hemiplegic migraine Familial hemiplegic migraine (FHM) Familial hemiplegic migraine type 1 Familial hemiplegic migraine type 2 Familial hemiplegic migraine type 3 Familial hemiplegic migraine, other loci Sporadic hemiplegic migraine Retinal migraine Chronic migraine Complications of migraine Status migrainosus Persistent aura without infarction Migrainous infarction Migraine aura-triggered seizure Probable migraine Probable migraine without aura Probable migraine with aura Episodic syndromes that may be associated with migraine Recurrent gastrointestinal disturbance Cyclical vomiting syndrome Abdominal migraine Benign paroxysmal vertigo Benign paroxysmal torticollis</p>\n<p><strong>Random:</strong></p><p>Explanation For Incorrect Options:- Option: A, C & D. Doesnâ€™t contain Familial hemiplegic migraine .</p>\n<p><strong>Extraedge:</strong></p><p>Familial hemiplegic migraine Hemiplegia with migraine Full recovery of focal neurological features within 24 hr Familial hemiplegic migraine (FHM) Involved channel Gene FHM1 Most common 50%cases Cav 2.1 (P/Q)â€“type voltage-gated calcium channel CACNA1A gene FHM2 20%cases Na+-K+ATPase ATP1A2 gene FHM3 Neuronal voltage-gated sodium channel SCN1A gene</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following is NOT a component of three drug combinations approved for use by the FDA for the treatment of mild to moderate migraine?", "options": [{"label": "A", "text": "Acetaminophen", "correct": false}, {"label": "B", "text": "Aspirin", "correct": false}, {"label": "C", "text": "Caffeine", "correct": false}, {"label": "D", "text": "Metoclopramide", "correct": true}], "correct_answer": "D. Metoclopramide", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Metoclopramide The combination of acetaminophen (paracetamol), aspirin, and caffeine has been approved for use by the FDA for the treatment of mild to moderate migraine.</p>\n<p><strong>Highyeild:</strong></p><p>Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Significantly reduces Severity of a migraine attack Duration of a migraine attack Many undiagnosed migraineurs self-treat with non-prescription NSAIDs. Most effective when taken early in the migraine attack. Efficacy is less than optimal in moderate or severe migraine attacks. Combinations- Acetaminophen (paracetamol), aspirin, and caffeine Approved for use by the S. Food and Drug Administration (FDA) Treatment of mild to moderate migraine . A spirin and metoclopramide shown to be comparable to a single dose of oral sumatriptan. Side effects Dyspepsia Gastrointestinal irritation.</p>\n<p><strong>Random:</strong></p><p>Explanation For Incorrect Options:- Option: A, B & C. are a component of three drug combinations approved for use by the FDA for the treatment of mild to moderate migraine.</p>\n<p><strong>Extraedge:</strong></p><p>Migraine attack Attack per month Headache duration Headache Treatment options Mild Less than 1 up to 8 hours Mild Simple analgesics/ NSAIDs or their combinations (Â± antiemetic) Moderate One or more attacks lasts for 6â€“24 hours more intense Functionally impaired. NSAIDs combinations/ a triptan/ ergot alkaloids (+ antiemetic) Severe 2â€“3 or more attacks severe throbbing headache often accompanied by for vertigo, vomiting, and other symptoms 12â€“48 hours grossly incapacitated A Triptan /ergot alkaloids (+ antiemetic) + Prophylaxis- 1. Propranolol/other Î² blockers 2. Amitriptyline/ other tricyclic antidepressants 3. Flunarizine/other Ca2+ channel blockers 4. Valproate/ topiramate</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 23-year-old patient presented with a complaint of severe throbbing. unilateral headache associated with nausea. what is the mechanism of drug used in acute treatment:", "options": [{"label": "A", "text": "Inhibition of 5-HT1A receptors", "correct": false}, {"label": "B", "text": "Inhibition of 5-HT1B receptors", "correct": false}, {"label": "C", "text": "Stimulation of 5-HT1A receptors", "correct": false}, {"label": "D", "text": "Stimulation of 5-HT1B receptors", "correct": true}], "correct_answer": "D. Stimulation of 5-HT1B receptors", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Stimulation of 5-HT1B receptors Patient has a unilateral, throbbing headache associated with nausea and is a case of migraine . Triptan causes Stimulation of 5-HT1B/1D receptors, which can stop an acute migraine attack.</p>\n<p><strong>Highyeild:</strong></p><p>Migraine Gender Female > male Site Unilateral Type Throbbing Duration One day Migraine associated features Nausea,vomiting Headache Phonophobia Osmophobia Movementâ†’ headache Disabling headache Auraâ†’ classical migraine (High risk of stroke) On examination Scalp tenderness Focal deficits (no neck stiffness) CGRP(Calcitonin Gene Related Peptide) Treatment NSAIDs Metoclopramide/ Prochlorperazine Triptans-5HT1B/1D agonist Ergot Caffeine STATUS MIGRANS (HEADACHE >72 hr) i. v. steroids Dopamine agonists v. ketorolac Hydration GEpants (Ubrogepant Rimegepant) Prophylaxis Beta-blockers (Propranolol,Timolol ) Valproate Topiramate Tricyclic antidepressants (Amitriptyline, Nortriptyline) Monoclonal antibodies [ Erenumab(s.c.) galcanezumab(s.c.) Eptinezumab(i.v.)] Botulinum toxin</p>\n<p><strong>Random:</strong></p><p>Explanation For Incorrect Options:- Option: A, B & C are incorrect</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 19-year female came to the emergency with a complaint of severe unilateral headache aggravated by movement. She also has nausea and phonophobia. By which route can you administer the drug for acute treatment of her headache?", "options": [{"label": "A", "text": "Nasal", "correct": false}, {"label": "B", "text": "Parenteral", "correct": false}, {"label": "C", "text": "Oral", "correct": false}, {"label": "D", "text": "Any of the above", "correct": true}], "correct_answer": "D. Any of the above", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Any of the above The cause is most probably Migraine type headache. (unilateral, throbbing type, associated with Nausea, photophobia, aggravated by movement). Acute treatment will be Sumatriptan. Which is available in Oral, Nasal, and Parenteral forms.</p>\n<p><strong>Highyeild:</strong></p><p>Triptans act as antimigraine agents by selectively binding to the serotonin receptors 5-HT1B and 5-HT1D. Triptan binding to the vascular 5-HT1B receptors leads to vasoconstriction of the cranial arteries, which painfully dilate during a migraine attack. Contraindications Coronary artery disease. 5-HT 1B/1D Receptor Agonistsâ€”Triptans Oral Ergotamine 1 mg, caffeine 100 mg Naratriptan Rizatriptan Sumatriptan Frovatriptan Almotriptan Eletriptan Zolmitriptan Nasal Dihydroergotamine Sumatriptan Zolmitriptan Parenteral Dihydroergotamine Sumatriptan</p>\n<p><strong>Random:</strong></p><p>Explanation For Incorrect Options:- Option: A. Nasal-eg. Nasal spray of sumatriptan,zolmitriptan Option: B. Parenteral-eg. Injection Sumatriptan Option: C. Oral-eg. Oral sumatriptan,Naratriptan etc.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following neuromodulation techniques is FDA approved for the treatment of migraine?", "options": [{"label": "A", "text": "Single-pulse transcranial magnetic stimulation (TMS)", "correct": false}, {"label": "B", "text": "Non-invasive vagus nerve stimulator (nVNS)", "correct": false}, {"label": "C", "text": "Both a and b", "correct": true}, {"label": "D", "text": "Used but not approved by FDA yet", "correct": false}], "correct_answer": "C. Both a and b", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Both a and b Single-pulse transcranial magnetic stimulation (TMS) and a non-invasive vagus nerve stimulator (nVNS) are FDA-approved for the treatment of Migrane.</p>\n<p><strong>Highyeild:</strong></p><p>FDA-approved nonpharmaceutical neuromodulation migraine treatment- Single-pulse transcranial magnetic stimulation (TMS) for the acute treatment of migraine. Two pulses can be applied at the onset of an attack, and this can be repeated. Safe where there is no cranial metal implant A noninvasive vagus nerve stimulator (nVNS) treatment of migraine attacks in adults. One to two 120-s doses may be applied for attack treatment Remote electrical neuromodulation Using a smartphone app Stimulates the upper arm for 30â€“45 min Transcutaneous supraorbital nerve stimulation for 60 min.</p>\n<p><strong>Random:</strong></p><p>Explanation For All Options:- Option A, B & C is better. Option D. These neuromodulation techniques are FDA approved.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following is the treatment of choice which can completely suppress paroxysmal hemicrania?", "options": [{"label": "A", "text": "Topiramate", "correct": false}, {"label": "B", "text": "Verapamil", "correct": false}, {"label": "C", "text": "Piroxicam", "correct": false}, {"label": "D", "text": "Indomethacin", "correct": true}], "correct_answer": "D. Indomethacin", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Indomethacin Indomethacin (25-75 mg tid) , can completely suppress attacks of paroxysmal hemicrania and is the treatment of choice for prevention of Paroxysmal hemicrania attack . Although therapy may be complicated by Indomethacin-induced gastrointestinal side effects , currently there are no consistently effective alternatives.</p>\n<p><strong>Highyeild:</strong></p><p>Trigeminal Autonomic Cephalalgias Cluster Paroxysmal hemicrania SUNCT SUNCT (Short lasting unilateral neuralgiform conjunctival tearing) Gender Male>Female Male=Female Male=Female Attack frequency 1/day to 8/day 1-20/day (more than 5/day) 3-200/day Attack duration 15 min-3hr (1hr) 2-30 min (15min) 5-240 sec (seconds) Cutaneous trigger No No YES Alcohol trigger YES No YES Migrainous YES YES YES Autonomic YES YES YES Reacts to Indomethacin No YES No Abortive Treatment Injection Triptans(DOC) O2 Not available Lidocaine preventive Verapamil Galcanezumab Indomethacin Lamotrigine (DOC) Topiramate Gabapentin</p>\n<p><strong>Random:</strong></p><p>Explanation For Incorrect Options:- Option: A.Topiramate is helpful in some cases. Option: B.Verapamil , an effective treatment for cluster headaches, does not appear to be useful for paroxysmal hemicrania. Option: C. Piroxicam has been used, although it is not as effective as Indomethacin.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "All of the following are Characteristics that lead to a suspected diagnosis of SUNCT except?", "options": [{"label": "A", "text": "Cutaneous (or other) triggers of attacks", "correct": false}, {"label": "B", "text": "Refractory period to triggering between attacks", "correct": true}, {"label": "C", "text": "The lack of a response to indomethacin", "correct": false}, {"label": "D", "text": "Apart from trigeminal sensory disturbance, normal neurologic examination", "correct": false}], "correct_answer": "B. Refractory period to triggering between attacks", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Refractory period to triggering between attacks A lack of refractory period to trigger between attacks are characteristics that lead to a suspected diagnosis of SUNCT (Short lasting unilateral neuralgiform conjunctival tearing).</p>\n<p><strong>Highyeild:</strong></p><p>Characteristics that lead to a suspected diagnosis of SUNCT (Short lasting unilateral neuralgiform conjunctival tearing) are the cutaneous (or other) triggers of attacks a lack of refractory period to triggering between attacks the lack of a response to indomethacin .</p>\n<p><strong>Random:</strong></p><p>Explanation For Incorrect Options:- Option: A & C. are characteristics of SUNCT (Short lasting unilateral neuralgiform conjunctival tearing) Option: D . Apart from trigeminal sensory disturbance , the neurologic examination is normal in primary SUNCT (Short lasting unilateral neuralgiform conjunctival tearing).</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 25-year-old female has severe excruciating burning retro-orbital pain, it lasts for around 30 seconds and she gets 50 attacks per day. Which of the following is the most effective treatment for the prevention of her condition ?", "options": [{"label": "A", "text": "Topiramate", "correct": false}, {"label": "B", "text": "Gabapentin", "correct": false}, {"label": "C", "text": "Carbamazepine", "correct": false}, {"label": "D", "text": "Lamotrigine", "correct": true}], "correct_answer": "D. Lamotrigine", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Lamotrigine This is a case of SUNCT (Short lasting unilateral neuralgiform conjunctival tearing) as the patient has burning retro-orbital pain(trigeminal Autonomic cephalgia) with each attack lasting only 30 sec and 50 attacks per day. The most effective treatment/Drug of choice for the prevention of SUNCT is Lamotrigine.</p>\n<p><strong>Highyeild:</strong></p><p>Trigeminal Autonomic Cephalalgias Cluster Paroxysmal hemicrania SUNCT SUNCT (Short lasting unilateral neuralgiform conjunctival tearing) Gender Male>Female Male=Female Male=Female Attack frequency 1/day to 8/day 1-20/day (more than 5/day) 3-200/day Attack duration 15 min-3hr (1hr) 2-30 min (15min) 5-240 sec (seconds) Cutaneous trigger No No YES Alcohol trigger YES No YES Migranious YES YES YES Autonomic YES YES YES Reacts to Indomethacin No YES No Abortive Treatment Injection Triptans(DOC) O2 Not available Lidocaine preventive Verapamil Galcanezumab Indomethacin (DOC) Lamotrigine (DOC) Topiramate Gabapentin</p>\n<p><strong>Random:</strong></p><p>Explanation For Incorrect Options:- Option: A & B.Topiramate and gabapentin- may also be effective.But, not the Drug of choice for the prevention of SUNCT (Short lasting unilateral neuralgiform conjunctival tearing). Option: C. Carbamazepine- has been reported by patients to offer modest But, not the Drug of choice for the prevention of SUNCT (Short lasting unilateral neuralgiform conjunctival tearing).</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following statements about hemicrania continua is FALSE?", "options": [{"label": "A", "text": "Moderate and continuous unilateral pain", "correct": false}, {"label": "B", "text": "The cause is unknown", "correct": false}, {"label": "C", "text": "Failure to resolve pain with indomethacin", "correct": true}, {"label": "D", "text": "Women are affected twice as often as men", "correct": false}], "correct_answer": "C. Failure to resolve pain with indomethacin", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Failure to resolve pain with indomethacin Hemicrania continua pain resolves completely with Indomethacin.</p>\n<p><strong>Highyeild:</strong></p><p>Hemicrania contÃ­nua Age of onset ranges from 10 to 70 years Women are affected twice as often as Features- Moderate and continuous pain Unilateral Fluctuations of severe pain Complete resolution of pain with indomethacin Exacerbations that may be associated with autonomic features Conjunctival injection Lacrimation photophobia on the affected side. The cause is unknown. Treatment- Indomethacin other NSAIDs- No benefit The IM injection of 100 mg of indomethacin vs placebo injection- Diagnostic tool Topiramate nVNS(NonInvasive Vagal nerve stimulation) Occipital nerve stimulation( Patients who are intolerable to Indomethacin )</p>\n<p><strong>Random:</strong></p><p>Explanation For Incorrect Options:- Option: A, B & D are true about Hemicrania Continua.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "The below condition is related to which of the following drugs (on repeated doses) is used in the treatment of Migraine?", "options": [{"label": "A", "text": "NSAIDs", "correct": false}, {"label": "B", "text": "Beta blockers", "correct": false}, {"label": "C", "text": "Ergotamine", "correct": true}, {"label": "D", "text": "Dopamine antagonists", "correct": false}], "correct_answer": "C. Ergotamine", "question_images": ["https://dbmi-data.s3.ap-south-1.amazonaws.com/photos-1683855115446-QTDM125020IMG1.JPG"], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Ergotamine The above condition is gangrene due to ergot use. The patient had taken repeated doses of ergotamine tartrate for Migraines. Ergotamine and Dihydroergotamine are used for the treatment of acute attacks of Migraines and act as nonselective 5HT1 agonists which decrease cerebral vasodilation and P a in They can also cause Vasospasms in limbs leading to gangrene.</p>\n<p><strong>Highyeild:</strong></p><p>Ergot alkaloids Ergotamine, methysergide, bromocriptine, pergolide A nonselective stimulation of 5-HT1 receptors Inhibition of Î±-adrenergic receptors Stimulation of dopamine receptors Dose A nonnauseating dose of ergotamine should be sought Because a dose that provokes nausea is too high and may intensify head pain. Oral (excluding sublingual) formulations of ergotamine also contains 100 mg caffeine (theoretically to enhance ergotamine absorption and possibly to add additional analgesic activity ). The average oral ergotamine dose for a migraine attack is 2 mg. Comparison with triptans A much higher incidence of nausea on ergot use than with triptans but less headache recurrence. Side effects Physiologic stimulation Formication vasospasm of limb (isolated or generalized ) â†’ gangrene Myocardial and cerebral ischemia to infarction . Hypotension Bradycardia Involuntary movements Treatment of side effects Severe vasospasm Nitroprusside or nitroglycerine Mild-to moderate limb ischemia Prazosin (an Î±1 blocker) Captopril Nifedipine Cyproheptadine (a serotonin receptor antagonist) For hallucinations and movement disorders dopamine receptor antagonists (antipsychotics)</p>\n<p><strong>Random:</strong></p><p>Explanation For Incorrect Options:- Option: A. NSAIDs- causes gastrointestinal side effects . Option: B. Beta blockers -is are used in the prevention of migraine not treatment. Option: D. Dopamine antagonists -is are used in the treatment of vomiting in migraine and do not cause gangrene.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following is false with regard to basilar migraine?", "options": [{"label": "A", "text": "It often occurs in children", "correct": false}, {"label": "B", "text": "characterized by a typical migrainous aura associated with numbness", "correct": false}, {"label": "C", "text": "Tingling sensation is not associated", "correct": true}, {"label": "D", "text": "Ataxia of gait with occasional impairment of consciousness", "correct": false}], "correct_answer": "C. Tingling sensation is not associated", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Tingling sensation is not associated Basilar migraine is characterized by numbness/ tingling in lips and extremities(Bilateral).</p>\n<p><strong>Highyeild:</strong></p><p>Migraine Characterized by Focal migraine Symptoms of migraine + Transient dysphagia Hemisensory symptoms Focal weakness Migraine sine Episodic visual disturbance without headache Elderly patients with a history of classical migraine are typically affected Retinal migraine Acute transient unilateral loss of vision Middle aged person without a history of migraine Ophthalmoplegic migraine Recurrent transient 3rd nerve palsy which begins after headache Familial hemiplegic migraine Hemiplegia with migraine Full recovery of focal neurological features within 24 hr Basilar migraine Occurs in children Typical migrainous aura associated with numbness tingling of lips and extremities(Bilateral) Ataxia of gait and speech Occasional impairment of consciousness.</p>\n<p><strong>Random:</strong></p><p>Explanation For Incorrect Options:- Options: A, B & D. are true about Basilar migraine.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following is false about the simplified diagnostic criteria for Migraine?", "options": [{"label": "A", "text": "Repeated attack of 4 to 72 hrs with normal neurological examination and no other reasonable causes for headache", "correct": false}, {"label": "B", "text": "At Least 2 of the following Headaches (a)Unilateral (b)Throbbing (c)Moderate to severe (d)Aggravated by exertion or routine physical activity (e)Headache 4hr-3 days", "correct": false}, {"label": "C", "text": "At Least 1 of the following of (a) nausea and vomiting (b) photophobia and phonophobia", "correct": false}, {"label": "D", "text": "None of the above", "correct": true}], "correct_answer": "D. None of the above", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>None of the above None of the above statements are false about the simplified diagnostic criteria for migraines .</p>\n<p><strong>Highyeild:</strong></p><p>Simplified Diagnostic Criteria of Migraine A. Any 2 out of 5 should be present 1.     Headache 4hr-3 days 2.     Unilateral 3.     Throbbing 4.     Moderate to severe 5.     Aggravated by exertion or routine physical activity B. C. At least 1 out of 2 should be present 1.     Nausea/vomiting 2.     Photophobia+phonophobia D. At least 5 attacks E. No organic disease</p>\n<p><strong>Random:</strong></p><p>Explanation For Incorrect Options:- Option: A, B & C. - are true about the simplified diagnostic criteria for Migraine .</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following is not true with regard to _gepants?", "options": [{"label": "A", "text": "It is used for acute treatment and prevention of Migraine", "correct": false}, {"label": "B", "text": "It acts as a CGRP antagonist and blocks this peptide", "correct": false}, {"label": "C", "text": "Acts by promoting vasoconstriction effect inhibiting of vasodilation Action of CGRP receptor", "correct": false}, {"label": "D", "text": "Acts on nitrergic neurons which are 2nd order CGRP Neurons", "correct": true}], "correct_answer": "D. Acts on nitrergic neurons which are 2nd order CGRP Neurons", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Acts on nitrergic neurons which are 2nd order CGRP Neurons Nitrergic neurons are first-order neurons releasing CGRP.</p>\n<p><strong>Highyeild:</strong></p><p>Oral depants: small-molecule CGRP receptor antagonists Mechanism of action: The calcitonin gene-related peptide ( CGRP ) is a strong vasodilator primarily found in nervous tissue. Nitrergic neurons are 1st order releasing CGRP Vasodilation in the Brain is involved in the development of Migraine and CGRP levels are increased during the Migraine attacks. Gepants act as a CGRP antagonist and block this peptide This constricts dilated blood vessels within the brain. And counters the vasodilation which is the cause of pain in Migraines. Indication: Acute treatment of migraine. FDA approved: Rimegepant-Both acute and preventive treatment Ubrogepant -Acute treatment Advantage: pain-free and most bothersome symptoms free at 2 hours The most bothersome symptom is derived by asking patients to identify which symptom-of nausea, photophobia, and phonophobia was most bothersome during the treated attack Well tolerated Side effects: mild nausea.</p>\n<p><strong>Random:</strong></p><p>Explanation For Incorrect Options:- Option: A, B & C are correct.</p>\n<p><strong>Extraedge:</strong></p><p>Monoclonal antibodies against CGRP approved for migraine prophylaxis: Erenumab(s.c.) galcanezumab(s.c.) Eptinezumab(i.v</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Triptans act by which of the following mechanisms:", "options": [{"label": "A", "text": "Decreasing cerebral vasodilation", "correct": true}, {"label": "B", "text": "Increasing cerebral vasoconstriction", "correct": false}, {"label": "C", "text": "Does not affect cerebral vessels", "correct": false}, {"label": "D", "text": "None of the above", "correct": false}], "correct_answer": "A. Decreasing cerebral vasodilation", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Decreasing cerebral vasodilation Triptans act as antimigraine agents by selectively binding to the serotonin receptors 5-HT1B and 5-HT1D. Triptan binding to the vascular 5-HT1B receptors leads to vasoconstriction of the cranial arteries, which painfully dilate during a migraine attack.</p>\n<p><strong>Highyeild:</strong></p><p>Acute migraine treatment: NSAIDS- Ibuprofen Naproxen Triptans 5HT 1B/1D agonists Ergot Dihydroergotamine nasal spray Diclofenac Antiemetics Dopamine antagonists- Metoclopramide prochlorperazine</p>\n<p><strong>Random:</strong></p><p>Explanation For Incorrect Options:- Options: B, C & D. are incorrect statements.</p>\n<p><strong>Extraedge:</strong></p><p>table,tr,th,td {border:1px solid black;} 5-HT 1B/1D Receptor Agonistsâ€”Triptans Oral Ergotamine 1 mg, caffeine 100 mg Naratriptan Rizatriptan Sumatriptan Frovatriptan Almotriptan Eletriptan Zolmitriptan Nasal Dihydroergotamine Sumatriptan Zolmitriptan Parenteral Dihydroergotamine Sumatriptan</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following is not a criterion to define aura in Migraine?", "options": [{"label": "A", "text": "Gradual in onset", "correct": false}, {"label": "B", "text": "Not fully reversible", "correct": true}, {"label": "C", "text": "followed by headache within 60 minutes or headache preceding or simultaneously with aura", "correct": false}, {"label": "D", "text": "lasting about 60 minutes", "correct": false}], "correct_answer": "B. Not fully reversible", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Not fully reversible The aura in migraine is fully reversible.</p>\n<p><strong>Highyeild:</strong></p><p>Aura is defined by at least 3 of the following Fully reversible Lasting for 60 minutes Gradual onset Followed by a headache within 60 minutes or a headache preceding or simultaneously with aura. Migraine Aura + Classical migraine Increased risk of stroke Estrogen â†’ OCPs (avoided) Aura - Without Aura Common migraine Aura: Typical -visual, sensory, dysphasic speech Hemiplegic migraine- one of the above +  motor weakness. table,tr,th,td {border:1px solid black;} Visual Aura Rating scale Visual symptom characteristic Risk score Duration 5-60 min 3 Develops gradually in more than or equal to 5 min 2 Scotoma 2 Zig-zag line(fortification) 2 Unilateral(homonymous) 1 Maximum VARS score 10 Migraine with aura diagnosis More or equal to 5</p>\n<p><strong>Random:</strong></p><p>Explanation For Incorrect Options:- Option A, C & D. are useful criteria to diagnose Aura with migraine.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "Which of the following is not used in the treatment of moderate and severe Migraine?", "options": [{"label": "A", "text": "5HT1B /1D agonists", "correct": false}, {"label": "B", "text": "NSAIDS", "correct": true}, {"label": "C", "text": "Triptans", "correct": false}, {"label": "D", "text": "Dopamine antagonist", "correct": false}], "correct_answer": "B. NSAIDS", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>NSAIDS NSAIDS (Diclofenac and naproxen) are not effective in the treatment of Severe forms of migraine.</p>\n<p><strong>Highyeild:</strong></p><p>Migraine attack Attack per month Headache duration Headache Treatment options Mild Less than 1 Up to 8 hours Mild Simple analgesics/ NSAIDs or their combinations (Â± antiemetic) Moderate One or more attacks lasts for 6â€“24 hours more intense Functionally impaired. NSAIDs combinations/ a triptan/ ergot alkaloids (+ antiemetic) Severe 2â€“3 or more attacks severe throbbing headache often accompanied by vertigo, vomiting and other symptoms 12â€“48 hours grossly incapacitated A Triptan /ergot alkaloids (+ antiemetic) + Prophylaxis- 1. Propranolol/other Î² blockers 2. Amitriptyline/ other tricyclic antidepressants 3. Flunarizine/other Ca2+ channel blockers 4. Valproate/ topiramate</p>\n<p><strong>Random:</strong></p><p>Explanation For Incorrect Options:- Option: A. 5HT1B /1D agonists and Triptans- are used in moderate and severe migraine treatment. Option: D. Dopamine antagonist used as antiemetic in mild/moderate/severe migraine.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 23-year-old female presented with a pulsatile throbbing headache lasting 15 hrs associated with nausea and vomiting. Which of the following is known in the pathogenesis of her condition?", "options": [{"label": "A", "text": "vasoactive neuropeptides", "correct": false}, {"label": "B", "text": "CGRP Calcitonin gene-related peptides", "correct": false}, {"label": "C", "text": "cGMP", "correct": false}, {"label": "D", "text": "Both a and b", "correct": true}], "correct_answer": "D. Both a and b", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Both a and b Female patient with a pulsatile throbbing headache lasting almost the entire day , associated with nausea and vomiting is typical for Migraine headaches. Migraine is mainly known to be mediated by increasing levels of vasoactive peptides, mainly increasing CGRP which causes vasodilation effect and Pain.</p>\n<p><strong>Highyeild:</strong></p><p>Pathogenesis of migraine- The sensory sensitivity that is characteristic of migraine is probably due to dysfunction of monoaminergic sensory control systems located in the brainstem and hypothalamus. Activation of cells in the trigeminal nucleus â†’ Release of vasoactive neuropeptides, particularly calcitonin gene-related peptide (CGRP), at vascular terminals of the trigeminal nerve and within the trigeminal nucleus. Centrally, the second-order trigeminal neurons cross the midline and project to the ventrobasal and posterior nuclei of the thalamus for further processing. Additionally, there are projections to the periaqueductal gray and hypothalamus , from which reciprocal descending systems have established antinociceptive effects. Other brainstem regions likely to be involved in descending modulation of trigeminal pain include the nucleus locus coeruleus in the pons and the rostral ventromedial medulla. Pharmacologic and other data point to the involvement of the neurotransmitter 5-hydroxytryptamine (5-HT; also known as serotonin) in migraine. There is dopamine receptor hypersensitivity in migraineurs, as demonstrated by the induction of yawning, nausea, vomiting, hypotension, and other symptoms of a migraine attack by dopaminergic agonists at doses that do not affect nonmigraineurs. Hypothalamic activation, anterior to that seen in cluster headache , has now been shown in the premonitory (prodromal) phase of migraine using functional imaging, and this may hold a key to understanding some part of the role of dopamine in the disorder. Migraine genes identified by studying families with familial hemiplegic migraine (FHM) reveal the involvement of ion channels, suggesting that alterations in membrane excitability can predispose to migraine. Functional neuroimaging has suggested that brainstem regions in migraine have specific involvement in Migraine.</p>\n<p><strong>Random:</strong></p><p>Explanation For Incorrect Options:- Option: C. cGMP is a second messenger molecule that modulates various downstream effects, including vasodilation , retinal phototransduction, calcium homeostasis , and neurotransmission.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 23-year-old female presented with a pulsatile throbbing headache lasting 10 hrs associated with nausea and vomiting. Which of the following drugs will you use in prophylaxis of her condition?", "options": [{"label": "A", "text": "Propranolol", "correct": true}, {"label": "B", "text": "Atenolol", "correct": false}, {"label": "C", "text": "Carvedilol", "correct": false}, {"label": "D", "text": "None of the above", "correct": false}], "correct_answer": "A. Propranolol", "question_images": [], "explanation_images": [], "explanation": "<p><strong>Solution:</strong></p><p>Propranolol</p>\n<p><strong>Highyeild:</strong></p><p>PREVENTIVE TREATMENTS FOR MIGRAINE Indications- Increasing frequency of migraine attacks with attacks that are either unresponsive or poorly responsive to abortive treatments four or more attacks a month. Commonly used Preventives- Beta-blockers Propranolol Metoprolol Timolol Anticonvulsants Valproate Topiramate Tricyclic antidepressants Amitriptyline Dosulepin Nortriptyline Venlafaxine Monoclonal antibodies against CGRP approved for migraine prophylaxis- Erenumab(s.c.) galcanezumab(s.c.) Eptinezumab(i.v.) Serotonin and tryptamine antagonist Pizotifen Neuromodulation Single-pulse transcranial magnetic stimulation (TMS) Onabotulinum toxin type A(Chronic migraine )</p>\n<p><strong>Random:</strong></p><p>Explanation For Incorrect Options:- Option B. Atenolol & C. Carvedilol- are Beta-blockers but not approved for migraine prophylaxis.</p>\n<p>@dams_new_robot</p>", "bot": "@dams_new_robot", "video": ""}, {"text": "A 35-year-old, male presented with frequent headaches on one side only. The pain is short-lived lasting 15 minutes and it is very severe. The pain is retroorbital and it is experienced all over the head. There are also complaints of tears coming from this patient